Phase 2 Study of PF-08634404 with Chemotherapy in Adults with Untreated Transformed Small Cell Lung Cancer

What this Trial Is About

Researchers are studying a new medicine called PF-08634404 for adults with Transformed Small Cell Lung Cancer T-SCLC, a rare and aggressive lung cancer that develops after certain treatments stop working. This Phase 2 trial aims to understand how well PF-08634404 works alone and in combination with chemotherapy. Participants must be adults diagnosed with T-SCLC who have not yet received treatment for this type of lung cancer, except possibly one cycle of chemotherapy, and have good organ function and physical condition. Participants will receive PF-08634404 combined with chemotherapy through intravenous IV infusions. After completing this combination treatment, they will continue receiving PF-08634404 alone as maintenance therapy. All treatments and infusions are administered at clinical study sites by trained medical staff. The study includes monitoring up to about one year for response to treatment and up to 90 days after the last dose for side effects. During the study, participants will have tumor assessments based on standardized criteria to measure treatment response. Safety will be monitored by recording adverse events and laboratory tests. Researchers will also collect samples to study how the medicine behaves in the body and whether participants develop antibodies against it. The total study duration extends up to approximately two years after treatment to assess longer-term outcomes such as survival and disease progression.

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer